About AlphaVax
AlphaVax is a Healthcare company based in Durham (United States) founded in 1997. Vaccines for infectious diseases and cancer immunotherapy are developed. AlphaVax offers products and services including AlphaVaccine Platform and Cancer Immunotherapy Vaccines. Its focus areas include Diversified Pharmaceuticals, Drugs, Life Sciences and Immunotherapy. Its legal entity is AlphaVax Inc. Its competitors include Roivant Sciences, AbbVie and Gilead; 1 of its 3 listed competitors has raised funding.
Company details
AlphaVax was founded in 1997 in Durham, United States, within the biotechnology sector. Vaccines targeting infectious disease prevention and cancer immunotherapy are produced by the company. Clinical trials are underway for alpha vaccine candidates against human cytomegalovirus, influenza A virus, and HIV-1. AVX901, a HER2-VRP vaccine for metastatic breast cancer, is among the products. Alphavaccine technology is out-licensed for specific disease and antigen applications to support commercialization.
- Headquarters Durham, United States
- SectorsHealthcare
- Website alphavax.com
- Social LinkedIn
- Legal Name Alphavax Inc.
- Latest Funding Round$135.19K (USD), Grant
May 2010
- InvestorsHHS
& 1 more
Products & Services of AlphaVax
AlphaVax offers a comprehensive portfolio of products and services, including AlphaVaccine Platform and Cancer Immunotherapy Vaccines.
Proprietary RNA vector for developing vaccines against infectious diseases.
Vaccines targeting cancers like breast and gastrointestinal types.
Funding Insights of AlphaVax
- Total Rounds 5
- Last Round Grant — $135,193
- First Round $1.83M
(Jul 2007)
- Investors Count 2
All 5 funding rounds of AlphaVax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2010 | $135,193 | Grant | – | – | |
| Jun 2009 | $1M | Grant | – | – | |
| Aug 2008 | $1M | Grant | – | – | |
| Jun 2008 | $1.83M | Grant | – | – | |
| Jul 2007 | $1.83M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in AlphaVax
AlphaVax has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for AlphaVax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AlphaVax
3 people are tracked at AlphaVax (3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Karen A. Scappaticci | Director | Board & advisors |
Steven B. Mizel | Director | Board & advisors |
Jonathan Gelles | Director | Board & advisors |
Complete people profiles for AlphaVax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AlphaVax
3 dated milestones of AlphaVax across 13 years, from founding to its latest funding, stage changes and deals.
- Founded AlphaVax is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Grant, of $135K.
Competitors of AlphaVax
AlphaVax has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Gilead.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others |
Detailed competitors of AlphaVax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as AlphaVax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AlphaVax
AlphaVax was founded in 1997 and raised its 1st funding round 10 years after it was founded.
AlphaVax is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
AlphaVax was founded in 1997 in Durham, United States, within the biotechnology sector. Vaccines targeting infectious disease prevention and cancer immunotherapy are produced by the company. Clinical trials are underway for alpha vaccine candidates against human cytomegalovirus, influenza A virus, and HIV-1. AVX901, a HER2-VRP vaccine for metastatic breast cancer, is among the products. Alphavaccine technology is out-licensed for specific disease and antigen applications to support commercialization.
AlphaVax's top competitors include Roivant Sciences, AbbVie and Gilead.
AlphaVax offers AlphaVaccine Platform and Cancer Immunotherapy Vaccines.
AlphaVax has 2 investors. Key investors include HHS, and Military Health.
AlphaVax operates through Alphavax Inc..